Radiopharm Theranostics Limited RADX
Set alert
1.08 USD -0.04 -3.26%
At close · Oct 30
1.08 0.00 0.00%
After hours · Oct 30, 4:02 PM ET
1.08 Day range 1.16
0.90 52-week range 10.63
- YTD
- -79.31%
- 1 year
- -79.11%
- Open
- 1.09
- Prev close
- 1.12
- Mkt cap
- 16.96M
- Vol
- 8.92K
- Avg vol
- 56.66K
- EPS
- -3.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.08
- High
- 1.16
- Forward P/E
- 0.00
- Beta
- 0.85
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.67
- 200-d avg
- 7.67
- 1y target
- 0.00
2Y chart
Signals (87)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| RSI: Oversold | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 24, 2026 | 2 months ago |
| RSI: Oversold | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 24, 2026 | 3 months ago |
| RSI: Oversold | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | May 14, 2026 | 5 months ago |
| MACD: Sell Signal | May 6, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 8, 2026 | 6 months ago |
| RSI: Oversold | Mar 24, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 19, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 17, 2026 | 8 months ago |
| SMA: Bearish | Feb 10, 2026 | 8 months ago |
| SMA: Bearish | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Feb 3, 2026 | 9 months ago |
| MACD: Sell Signal | Feb 3, 2026 | 9 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Jan 30, 2026 | 9 months ago |
| SMA: Bearish | Jan 29, 2026 | 9 months ago |
| SMA: Bullish | Jan 28, 2026 | 9 months ago |
| SMA: Bearish | Jan 23, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 9, 2026 | 9 months ago |
| SMA: Bullish | Jan 9, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| RSI: Overbought | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 20, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 30, 2025 | 1 year ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 30, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 23, 2025 | 1 year ago |
| RSI: Overbought | Sep 16, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 11, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| RSI: Overbought | Aug 20, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| SMA: Bullish | May 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 25, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 18, 2025 | 1 year ago |
| RSI: Overbought | Mar 5, 2025 | 1 year ago |
| SMA: Bullish | Feb 25, 2025 | 1 year ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 9.52B
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 69.02
- EPS (TTM)
- -0.08
- Beta
- 0.85
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.96M
- Revenue growth
- 0.00%
- Free cash flow
- -12.04M
- Total cash
- 18.58M
- Total debt
- 0
- Return on equity
- -131.49%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 7.67
- 200-day average
- 7.67
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
RADX Revenue — annual 2.77M
RADX Net income — annual -54.53M
RADX EPS — annual -5.37
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. The company was incorporated in 2021 and is based in Carlton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- radiopharmtheranostics.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Radiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Radiopharm Says Data From Interim Analysis Of Phase 2b Imaging Clinical Trial Of 18F-RAD101 In Participants With Suspected Recurrent Brain Metastases From Solid Tumors Selected For Presentation At SNO26 Annual Meeting
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Radiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma
- Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
- Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of RV-01 In Patients With B7-H3 Expressing Tumors
- Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Your note
Sign in to keep a note on RADX — it syncs with the Stock Master app.